Table 1.

Clinical parameters of the examined breast cancer cases

HLA-G+ (27 cases)HLA-G (9 cases)Total (36 cases)
Mast cell–cancer cell interaction12 (44.4%)4 (44.4%)16 (44.4%)
(with ly+ and/or pN+)11/121/412/16
Gender
 Female27 (100%)9 (100%)36 (100%)
Age, y59.4 ± 2.6059.3 ± 3.0359.4 ± 2.07
Surgical procedure
 Mastectomy27 (100%)9 (100%)36 (100%)
pT stage
 (y)pT113 (48.1%)5 (55.6%)18 (50%)
 (y)pT212 (44.4%)3 (33.3%)15 (41.7%)
 (y)pT32 (7.4%)1 (11.1%)3 (8.3%)
pN stage
 (y)pN09 (33.3%)6 (66.7%)15 (41.7%)
 (y)pN113 (48.1%)3 (33.3%)16 (44.4%)
 (y)pN21 (3.7%)0 (0%)1 (2.8%)
 (y)pN34 (14.8%)0 (0%)4 (11.1%)
Lymphvascular invasion
 Positive5 (18.5%)0 (0%)5 (13.9%)
 Negative22 (81.5%)9 (100%)31 (86.1%)
Preoperative chemotherapy
 Present8 (29.6%)2 (22.2%)10 (27.8%)
 Absent19 (70.4%)7 (77.8%)26 (72.2%)
Histologic grading
 Grade 16 (22.2%)2 (22.2%)8 (22.2%)
 Grade 212 (44.4%)3 (33.3%)15 (41.7%)
 Grade 39 (33.3%)4 (44.4%)13 (36.1%)
Molecular subtype
 Luminal A10 (37.0%)5 (55.6%)15 (41.7%)
 Luminal B9 (33.3%)2 (22.2%)11 (30.6%)
 HER21 (3.7%)0 (0%)1 (2.8%)
 Luminal-HER24 (14.8%)0 (0%)4 (11.1%)
 Triple negative3 (11.1%)2 (22.2%)5 (13.9%)